Jan Skvarka insider trades: Zentalis Pharmaceuticals (ZNTL) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jan reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | ZNTL | ↑ Buy | 60,000 | $1.72 | $103K | Direct | Feb 4, 2025 (4d) |
| Sep 11, 2023 | ZNTL | ↓ Sell | 5,000 | $25.05 | $125K | Direct | Sep 13, 2023 (2d) |
| May 12, 2021 | TRIL | ↓ Sell | 130,500 | $9.21 | $1.2M | Direct | May 13, 2021 (1d) |
| Jan 14, 2021 | TRIL | ↓ Sell | 25,000 | $15.03 | $376K | Direct | Jan 15, 2021 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZNTL insiders
Open-market trades in the last 12 months
About Jan Skvarka's insider trades
Jan Skvarka is a director at Zentalis Pharmaceuticals (ZNTL). Since Jan 14, 2021, Jan has reported 1 open-market purchase worth $103K and 3 sales worth $1.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZNTL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.